Shauna Rago, APRN
Nurse Practitioner · Willimantic, CTNPI 1457544728
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by GSK at 30.6% of the total. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$1K
- Lilly USA, LLC$475
- Novo Nordisk$376
- AstraZeneca$233
- Exact Sciences$170
- plus $1K from 27 others
What the payments were for
- Food & beverage$5,567100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $1,705 |
| AbbVie | 73 | $1,141 |
| Lilly USA, LLC | 21 | $475 |
| Novo Nordisk | 20 | $376 |
| AstraZeneca | 11 | $233 |
| Exact Sciences | 6 | $170 |
| Pfizer | 8 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $138 |
| Amarin Pharma, Inc. | 8 | $132 |
| Merck | 7 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $89 |
| Boehringer Ingelheim | 5 | $88 |
| Sumitomo Pharma America, Inc. | 3 | $83 |
| Actelion Pharmaceuticals US, Inc. | 4 | $82 |
| Astellas Pharma US Inc | 3 | $75 |
| Bayer | 3 | $71 |
| Baxter Healthcare | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Seqirus USA Inc | 1 | $24 |
| Amgen | 1 | $23 |
| Sanofi | 1 | $22 |
| Abbott | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Viatris Specialty LLC | 1 | $18 |
| Covis Pharma GmbH | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$5,567 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $81,908 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $62,890 |
| FarxigaDapagliflozin Propanediol | 16 | $20,918 |
| JardianceEmpagliflozin | 25 | $20,726 |
| EliquisApixaban | 26 | $20,567 |
| MyrbetriqMirabegron | 19 | $9,962 |
| VascepaIcosapent Ethyl | 20 | $8,492 |
| TrintellixVortioxetine Hydrobromide | 11 | $7,259 |
| Atorvastatin Calcium | 223 | $2,174 |
| SynthroidLevothyroxine Sodium | 15 | $1,900 |
| Nebivolol Hcl | 20 | $1,470 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,339 |
| Levothyroxine Sodium | 122 | $1,108 |
| Pantoprazole Sodium | 78 | $1,067 |
| Escitalopram Oxalate | 125 | $1,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $376 | $81,90872 claims |
| GSKTrelegy Ellipta | $1,705 | $62,89082 claims |
| AstraZenecaFarxiga | $233 | $20,91816 claims |
| Boehringer IngelheimJardiance | $88 | $20,72625 claims |
| PfizerEliquis | $159 | $20,56726 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $9,96219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $138 | $7,25911 claims |
| AbbVieSynthroid | $1,141 | $1,90015 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $1,108122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Other nurse practitioner in Willimantic
- Lindita VincaCheshire$427K
- Catherine MilnePlymouth$361K
- Michele NovellaDanbury$331K
- Tiffany RydzNewtown$49K
- Paul FidrychNorwich$23K
- Priscilla QuilterNorwich$21K
- Kimberly BoldonMiddletown$19K
- Emma RobinsonStamford$17K
- Janice TavaresBridgeport$17K
- Kelly WilberWaterbury$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.